Cerebrolysin as Early add-on to REperfusion therapy and risk of HEmorrhagic Transformation after Ischemic Stroke (CEREHETIS). A prospective randomized active-control multicenter pilot study
Latest Information Update: 30 Mar 2023
Price :
$35 *
At a glance
- Drugs FPF 1070 (Primary) ; Alteplase
- Indications Stroke
- Focus Therapeutic Use
- Acronyms CEREHETIS
- 22 Feb 2021 New trial record